DTx West 2019

February 26 – 28 | San Mateo, CA

DTx West 2020 (February 17 – 19) is now open for advance bookings!

Defining How to Achieve Commercial and Patient Success with Digital Therapeutics

DTx West
 Partners 2019

DTx West Partners

DTin 60 Seconds

Key Numbers of DTx



Be part of the 200+ person audience of senior executives who are driving forward the development of Digital Therapeutics


Expert Speakers

Learn from the industry-defining speaker faculty, comprised of the pioneers of the industry and the most exciting new-comers


Hours of Networking

The audience is the  who’s who of the industry. From every leading Digital Therapeutic company to Pharma, HCP’s and Investors

What people are saying about DTx

“I found this conference eye-opening and had many interesting conversations. I am blown away by the Digital Therapeutics community and its commitment to value-based care”

Founder and Executive Director, Cures Within Reach for Cancer
Laura Kleiman

“DTx is the must attend event in our industry”

CEO, Akili Interactive
Eddie Martucci

“The DTx Series is a fantastic set of meetings. The quality of the investors, entrepreneurs and companies never fails to impress me, and I always leave having learned a lot”

General Partner, JAZZ Venture Partners
John Spinale

“The conference was tangible, specific and open. I have never been to a conference of this size with such richness of discussion”

Health Data Policy Director, Novartis
Frederico Calado

“Thanks for catalyzing the industry forward in this emerging field.  Looking forward to the next one”

Global Director, Innovation, Johnson and Johnson Technology
Cris de Luca

“DTx is an inclusive event, where the participants truly believe that the rising tide will raise all boats”

Founder and CEO, MyMee Inc 
Mette Dyhrberg

Expert Speaker Faculty

Matt Cook

Vice President, Commercial Strategy & Business Development, Omada Health

Anand Iyer

Chief Strategy Officer, WellDoc

Anand is a respected global digital health leader—most known for his insights on and experience with technology, strategy and regulatory policy. Anand has been instrumental in WellDoc’s success and the development of BlueStar®. Since joining WellDoc in 2008, he has held core leadership positions that included Chief Data Science Officer, President and Chief Operations Officer. He holds an MS and a PhD in electrical and computer engineering, and an MBA from Carnegie Mellon University

Stephanie Tilenius

CEO, Vida Health

Stephanie Tilenius is the Founder and CEO of Vida Health, a digital therapeutics platform that helps individuals overcome chronic mental and physical health conditions once and for all. Vida is deployed at Fortune 500 companies, large national payers, and providers.

Prior to starting Vida, Tilenius was with Kleiner Perkins Canfield & Byers, where she worked primarily with late-stage KPCB portfolio companies, with an emphasis on companies in the Digital Growth Fund.

Prior to Kleiner, Stephanie was at Google, where she was Vice President of Global Commerce and Payments, helping build and launch new products and platforms including Google Wallet, Google Shopping and Google Express.

Before Google, she was at eBay and PayPal for nine years. In her last role, she was SVP of eBay.com and Global Product, where she helped lead the eBay Marketplace turnaround from negative to positive double-digit growth.

Prior to eBay, Stephanie was VP of Merchant Services at PayPal where she built the off-eBay PayPal business from the ground up into a multi-billion business.

Today, she is using her experience in building engaging consumer products to transform healthcare. Vida combines digital therapies with one-on-one health coaching and evidence-based programs to help individuals overcome costly chronic conditions like obesity, diabetes, COPD, and depression.

Javier Garcia Palacios

Director, Digital Health Ventures, Bayer, #G4A

I am a chemical engineer by education. After my PhD on chemical processes at the Max Planck Institute, I dedicated the first 7 years of my professional life to the chemical industry at companies such as BASF, and Covestro. After several positions in R&D with focus on disruptive innovation and high risk initiatives, I joined the marketing team to develop new businesses for high performance materials in the electronic segment. As part of this role, I elaborated a proposal to transform the existing wound care materials into a new application field, wearables. This brought me closer to the field of Health and awoke my passion for health and wellness as an industry. It was then, in 2015, when I decided to join Bayer HealthCare to drive the digitalization efforts, leading Bayer’s Digital Health Incubator. In 2017 and under the umbrella brand of #G4A we brought many talented individuals with one ambition, “change the experience of health”. Since then, my role heading the Ventures team has been focusing on creating businesses that unlock new revenue streams and boost existing ones, improving people’s life in a connected world.

Mette Dyhrberg

CEO, Mymee

Eddie Martucci

CEO, Akili Interactive Labs

Eddie co-founded Akili Interactive Labs, and as part of PureTech has co-founded two other health-focused start-ups, and helped launch their digital health initiative. He was previously a Kauffman Entrepreneur Fellow, a program sponsored by the Kauffman Foundation of Kansas City, MO, focused on healthcare entrepreneurship. Prior to that, he completed his graduate work at Yale University in the Departments of Pharmacology and Molecular Biophysics & Biochemistry, focusing on structure-based drug design, where he led a research project that identified two novel chemical scaffolds as proof-of-concept compounds for novel therapy. Eddie received his B.S. in Biochemistry from Providence College, and his M.Phil. and Ph.D. from Yale University.

Brian Harris

Co-Founder & CEO, MedRhythms Inc.

Alex Waldron

Chief Commercial Officer, Pear Therapeutics

Alex is a senior level global bio/pharmaceutical business leader with 27+ years of experience with large pharmaceutical, fully integrated biopharmaceutical and startup organizations. He has a proven record of building and leading business strategy and operations. In his career, Alex has driven enterprise value from portfolio strategy through to commercial launch. In previous roles, Alex has architected the structure and growth of several divisions at Biogen and helped to shape the emerging biosimilar market at Epirus Biopharmaceuticals. Alex has also worked in numerous commercial and operations roles at Genzyme, Astra Zeneca, Pfizer and Bristol-Myers Squibb.

André Heeg

Head of Digital, Sandoz

André is an experienced startup executive, business and sales manager, leader, and strategist. He is an expert in inside and field sales management, pharmaceutical and medical products marketing and sales, commercial strategy planning, and healthcare topics. He has extensive knowledge in B2B and B2C business, software and hardware product portfolios and offerings in the US and Germany. His passion for the impact technology can have on a large scale has been the red thread throughout his career. André holds doctorates from the University of Würzburg in medicine and the University of Freiburg in dental medicine.

André joined Sandoz in June 2018 from his role as CSO at Thermondo GmbH, an integrated energy company offering state-of-the-art energy efficiency services and applying digital process excellence and quality management. This year, The Financial Times named Thermondo #2 fastest growing company in Europe as well as one of the 100 most influential clean-tech companies in the world.
Before that, André was Vice President of Local Sales at Zocdoc, Inc. Zocdoc is an online service that identifies in-network neighborhood physicians, books appointments, shares patient reviews, provides appointment and check-up reminders, and automatically fills in paperwork. Zocdoc is free for patients and available across the United States.

Chris Wasden

Head of Pharma, Happify

Megan Jones-Bell

Chief Scientific Officer, Headspace

Dr. Megan Jones Bell is Chief Science Officer at Headspace, a leader in the field of digital health and a visionary in making mental health care more effective, affordable, and accessible to all populations. Megan leads the company’s seven-person Health and Science team, which focuses on clinically validating the benefits of meditation with Headspace and commercializing the product within healthcare. Megan also oversees the 65+ clinical research studies conducted by Headspace’s academic partners.

Joel Sangerman

Chief Commercial Officer Click Therapeutics

Joel serves as Chief Commercial Officer for Click Therapeutics. Click develops software as prescription medical treatments to improve the lives of patients throughout the world.

For over 25 years Joel has helped payers, employers, providers and suppliers achieve better patient outcomes at a lower cost of care using new health technology. Helping to lead the charge for healthcare innovation, Joel will share how employers, insurers, and other healthcare payers are adopting Click’s clinically-validated digital therapeutics as key components to population health strategies.

While at Johnson & Johnson as Director of Payer Relations and with Walgreens as Vice President of Market Development Joel initiated pay for performance and shared savings models of value-based purchasing with payers and health systems. Joel also led commercial efforts with Sanofi Aventis to help providers contain the exploding costs associated with chronic conditions such as diabetes and cardiovascular disease.

Joel graduated from DePaul University in Chicago and later completed a Fellowship in healthcare leadership with the Washington DC based Advisory Board Company.

Rosemary Ku

Urgent Care Physician Kaiser Permanente | Founder, Executive Director, Cure Chronic Disease

Rosemary Ku, MD/MBA/MPH, is a practicing physician dual-board certified in Internal Medicine and Preventive Medicine. She is the Chief Medical Officer of Lark Health and founder of Cure Chronic Disease, the only digital health nonprofit dedicated to reversing multiple chronic diseases at scale. Previously, Rosemary was the Chief Medical and Strategy Officer of Restore Health which was acquired by Zillion in 2017. She completed residency at Kaiser Permanente San Francisco and medical school at Columbia University College of Physicians and Surgeons. She obtained her MPH in Health Policy and Administration from UC Berkeley and MBA from Columbia Business School. Rosemary majored in Molecular Biology with a certificate in Neuroscience at Princeton University.

David Stevenson

Managing Director, Merck Global Health Innovation Fund

Edward Cox

CEO, Dthera Sciences

Edward Cox was appointed as the new Chairman of the Board and the Chief Executive Officer of Dthera in connection with the closing of the EveryStory Transaction. Mr. Cox also continues to serve as EveryStory’s President and Chief Executive Officer and Chairman and a member of EveryStory’s Board of Directors, positions he has held since February 6, 2015. Prior to that, he served as a Vice President and Executive Officer of Apricus Biosciences, Inc., a publicly traded company, since December 2009, in roles leading Commercial Development, Business Development, Investor Relations, and Corporate Development. Mr. Cox holds a Master of Science in Management degree from the Warrington College of Business Administration at the University of Florida.

Joe Slavinsky

VP, Business Development, Propeller Health

Brent Vaughan

CEO & Co-Founder, Cognoa

Brent is the CEO and co-founder of Cognoa, an AI-based digital precision medicine behavioral health platform. Cognoais developing innovative digital diagnostics and digital therapeutics to change the standard of care for pediatric behavioral health and improve outcomes by enabling earlier diagnosis, treatment, and increased engagement. Brent has over 20 years industry experience working with diagnostics, therapeutics and digital consumer health. Prior to Cognoa, Brent was the co-founder and COO of WellnessFX, an award-winning digital health company that increased patient engagement by providing direct-to-consumer diagnostics and integrated telemedicine. Before working in digital health, Brent worked in product and commercial roles in Novartis, Nektar, Roche and Lily.

David Amor

VP, Quality & Regulatory Affairs, Pear Therapeutics

David Amor is an FDA/ EU Quality/ regulatory expert focused on combination products and digital health. From NDAs and 505(b)(2)s to mobile app 510(k)s and Pre-INDs/ Q-subs, David has worked with over 45 medical device and pharmaceutical companies – large and small alike- supporting and/ or leading regulatory submissions and implementing quality management systems, including alignment of Agile-based SDLC programs to FDA and EU requirements. He co-founded RemindTrac in 2014 (www.remindtrac.com), a digital health company for chronic patients, that continues to pioneer mobile care management systems today, and sold his consulting firm Medgineering in 2016.

David has recently led QA/RA strategy groups at Teva within the Digital Health Group, particularly in development of Agile-based Quality Management Systems, was a Principal Consultant in the CP/DH (Combination Products, Digital Health) group at Qara Partners, and served as the in-house risk management subject matter expert at Abbott (St. Jude Medical). He has served as the Director or VP of Quality at other medical device start-ups including AdrenaCard, Calcula, Enspero Medical and various others, and led multiple organizations through 483 and Warning Letter remediation projects, namely associated with risk management and design history file deficiencies, including Pfizer (Hospira), MID, Boston Scientific and St. Jude Medical.

Ruchita Sinha

Senior Director, Investment, Sanofi Ventures

Ruchita Sinha is Sr. Director of Investments at Sanofi Ventures where she invests in biopharma and digital health opportunities. She led Sanofi’s investments in Inozyme, Omada Health, Evidation Health, Curisium, and also manages investments in Science 37 and Common Sensing. Prior to Sanofi, Ruchita was at GE Ventures, where she served as a board observer for HeadSense Medical and Caremerge and managed GE’s investments in CheckCap (Nasdaq: CHEKU) and HeartFlow. She also managed GE’s seed-stage portfolio of digital health investments in partnership with StartUp Health.

Ruchita has more than 15 years of healthcare experience in pharma, biotech, medical devices, and digital health. Previously, Ruchita was at Pfizer’s Strategy, BD, & Portfolio Management group, and a management consultant with LEK Consulting. Ruchita started her career with Maxygen, an early stage biotech company. She holds an MBA from the University of Chicago, an MS in Cellular and Molecular Biology from the University of Wisconsin-Madison, and a BS in Biochemistry from Mount Holyoke College.

Giangiacomo Rocco di Torrepadula


Sharief Taraman

Chief Medical Officer, Cognoa | Chief of Neurology, Children’s Hospital of Orange County

Taylor Mahan-Rudolph

Director, Quality & Regulatory, Propeller Health

David Kim

CEO, DigiTx Partners

David is the CEO of DigiTx Partners, bringing both business and clinical expertise to venture capital with an extensive background practicing medicine and building healthcare software companies. Most recently, Dr. Kim served as the COO of Lumiata, a venture-backed predictive analytics company positioned at the intersection of data science and medical science. Prior to Lumiata, he spent over a decade as an investor evaluating and growing healthcare companies at MPM Capital and Pinnacle Ventures. Before entering the business sector, David practiced as a general internist and hospitalist at Kaiser South San Francisco where he also served as the Director of Urgent Care and Assistant Chief of Internal Medicine.

Shahram Seyedin-Noor

Founder & General Partner, Civilization Ventures

Shahram is the Founder and General Partner of Civilization Ventures, a fund focused on supporting cutting-edge innovations in synthetic biology and health tech, including genomics, diagnostics, AI and regenerative medicine. Founded in 2017, Civilization VC has already been recognized by SVB as one of the most active funds in diagnostics. The fund’s disruptive seed portfolio includes CatalogDNA and Evonetix, as well as gene therapy leader Rocket Pharma (NASDAQ: RCKT). Prior to starting Civilization VC, Shahram was a founding executive in several life sciences companies, including Rgenix, a biotech company with first-in-class cancer drugs now in clinical trials, and NextBio, a big data genomics pioneer which he helped grow to over 50 people with millions in sales before it was acquired by Illumina. As an angel investor earlier in his career, Shahram provided the first check into Omada Health and was a seed investor in Counsyl (acq. by Myriad), Bina (acq. by Roche) and Avantome (acq. by Illumina). Shahram obtained his JD from Harvard Law School, where he was elected Editor-in-Chief of the Harvard International Law Journal, and has a BA in Economics from Pomona College.

Matthias Zenker

Partner, GAIA AG

Matthias is a physician by training and holds a medical doctorate degree from the University of Ulm, Germany. He has gained both inpatient and outpatient medical expertise in various healthcare systems around the world. Matthias joined GAIA 17 years ago and takes the responsibility for the national and international business development and licensing activities with payer and physician organisations as well as industry partners. And when not travelling the world for business, he travels the world for leisure.

Chris Raine

Founder & Chief Executive Officer, Hello Sunday Morning

Chris is the Founder and CEO of Hello Sunday Morning - an organisation that builds digital therapeutics focused on supporting people to change their relationship with alcohol.

Austin Speier

Chief Strategy Officer, Click Therapeutics

Sasha Said

Vice President, Leerink Transformation Partners

LTP is a $313M growth equity fund investing exclusively in digital health and healthcare services. Sasha K. Said is a founding member of the LTP investment team where she sources and structures deals; provides representation for LTP on the Board of Directors; and provides strategic and tactical support to portfolio companies. She has 10 years of investing experience across asset classes, 4 of which were spent with Waypoint Capital, the multi-billion dollar investment group that represents the Bertarelli family. While there she helped launch a $2B life science fund, Gurnet Point Capital, now managed by Chris Viehbacher (former CEO of Sanofi), as well as built their corporate venture group with a strategy in digital health. Prior to Waypoint, Sasha was a Global Long/Short Public Equity and Private Equity Analyst at Water Asset Management, a global hedge fund in New York City.

Sasha serves as a Board Observer on the Boards of Vera Whole Health and Health Catalyst and is a Board Member of Rimedio, an early stage pharma services company. She is founder of Breaking7% (B7), a group of 122 women (51% senior/ 49% junior) in deal making roles in Boston who meet monthly to exchange deals and contacts. She is also an Advisor to Pulse companies, Massachusetts’ digital health accelerator.

Peter Hames

Co-Founder & Chief Executive Officer, Big Health

Peter Hames is co-founder and CEO of Big Health, a company creating “digital medicine” - automated, digital, behavior change programs for mental health that are as scalable as drugs yet as effective as in person therapy. Peter is an NHS Innovation Fellow, and holds a Masters in Experimental Psychology from Oxford University. It was his own experience of insomnia, and how he overcame it, that inspired him to found Big Health and create Sleepio, a digital sleep improvement program that is now available to over 1 million employees as part of their benefits package.

Debra Reisenthel

Founding CEO, Palo Alto Health Sciences

Debra is founding CEO of Palo Alto Health Sciences, a digital therapeutic company providing evidence-based, at-home, drug-free solutions in behavioral health. Freespira® is an FDA-cleared treatment for panic disorder, panic attacks and PTSD. Debra has broad operational and leadership experience in start- ups, corporate and nonprofit organizations. Prior to PAHS, Debra worked with a Bay Area incubator to develop a women’s health product, was founding CEO of Novasys Medical, and was VP/GM of a Division of Tyco, inc. (Mallinckrodt, Nellcor). Debra holds a B.A., MBA and R.R.T credentials. She has been a guest entrepreneur for 5 years as part of an HBS case study. Given her deep knowledge of digital therapeutics and medical devices, she is now an Advisor to DTxCC and a Consultant in this growing market.

Owen McCarthy

Co-Founder & President, MedRhythms Inc.

Stacey Curtiss

Senior Director & Leader, Medical Science Liaisons, Akili Interactive

Stacey Curtiss, PharmD, is Senior Director & Leader of the Medical Science Liaison Team at Akili. She has broad Neuroscience Medical Affairs experience ranging from developing medical strategy to the creation and leadership of Medical Science Liaison Teams that educate clinicians and obtain insights on unmet needs in the care of patients. Prior to joining Akili, Stacey was the Vice President, Global Lead, Medical Science Liaisons at Ironshore Pharmaceuticals. Prior to that, she served as the East Regional Lead of the Neuroscience MSL Team at Shire. She received her Doctor of Pharmacy degree with High Distinction from the University of Iowa College of Pharmacy in Iowa City, IA, and subsequently completed a Pharmacy Practice Residency at the VA Medical Center in Portland, Oregon.

Austin Speier

Chief Strategy Officer, Click Therapeutics

Adam Kaufman

President & Chief Executive Officer, Canary Health

Adam Kaufman is a health pioneer, having led the building of digital behavior change programs used by dozens of healthcare organizations and tens of thousands of consumers. A health economist, engineer and company executive, Adam speaks to audiences nationwide on the accelerating trend of chronic illness, its impact on lives and costs of care and proven approaches to arresting disease trajectories.
Recognized as a leader in patient engagement and population health, Canary Health works with health plans such as Kaiser Permanente, Humana, GEHA and Blue Shield of California to empower members to better health self-management.

Jeffrey Abraham

Vice President, Market Access & Trade, Akili Interactive

Florian Schubert

Director, Digital Strategy, Sandoz

Florian started his career working in Silicon Valley for an Equity Research firm focused on technology and renewable energy companies. He continued working for Google advising clients from the energy and retail industry. Before joining Sandoz he worked four years for a Berlin-based start-up in sales operations and product management. At Sandoz his primary focus are Digital Therapeutics.

James Musick

Vice President & Head, Neurology Patient Technology, UCB

Vishal Dubey

Chief Product Officer, AMICOMED

Vishal Dubey is the head of products for Amicomed, a digital therapeutics pioneer for blood pressure management. He also serves as a board advisor to several silicon valley based startups and investor groups. Vishal specializes in digital and health-tech products with his expertise in software, product design and several years of experience within the US healthcare ecosystem.

Previously, Vishal has worked in various leadership and innovation roles at Kaiser Permanente, Accenture, Facebook, Dacadoo, and HealDeal. At Kaiser, Vishal served as Director of Digital Health, where he led innovation and mobile health initiatives spanning from patient engagement to care provider enablement. As an early pioneer of digital health, Vishal launched his first company HealDeal back in 2007, to offer price transparency and cost comparison tools to US healthcare consumers. Since then he has envisioned and built products for corporate health, health risk analysis, wellness & prevention, care management and remote care.

Vishal is a frequent speaker at industry forums and mentors entrepreneurs from silicon valley based institutions and groups including StartX, Astia and Stanford Bio Design. He advises companies on product design and go-to market strategy with Employers, Insurers, Providers and Channel partners. Vishal has an engineering background with a dual Masters in Industrial Engineering and Computer Science, along with an MBA from UC Davis.

Veera Anantha

Founder, CTO & President, The Learning Corp

Matthew Tucker

Executive Director, Marketing Strategy, Highmark Health

Matthew Tucker helps healthcare companies solve complex commercial problems so they can grow bigger and faster. With extensive experience leading commercial planning and execution across functional areas, Mr. Tucker has leveraged his leadership roles at Highmark Health, Baxter, Mylan, and a number of startups. Over the course of his career, he has led significant growth in health plan initiatives and of more than 20 medical device and pharmaceutical brands.

David Lee

Partner, Simon Kucher & Partners

David Lee is a Partner within the Life Sciences division at Simon-Kucher. David’s focus is on helping clients in the transition to a digital business.

Specifically, David helps digital, medical technology, and pharmaceutical clients drive growth through monetization strategy, sales force optimization, key account negotiation, and commercial excellence programs with an eye toward digitalization.

Kim Cornish

Director, Monash Institute of Cognitive & Clinical Neurosciences (MICCN), Co-Inventor of Tali Train Monash University

Professor Kim Cornish is the Director for the Monash Institute of Cognitive and Clinical Neurosciences (MICCN). She is a pioneer in the field of cognitive neuroscience, having defined attention pathways and their trajectories across development in children with brain disorders. This work has provided the foundation for TALI Train - the world’s first interactive, game-based attention training program for children with attention deficits.

Megan Coder

Executive Director, Digital Therapeutics Alliance

Megan Coder, PharmD, MBA, is Executive Director of the Digital Therapeutics Alliance. DTA’s mission is to broaden the understanding, adoption, and integration of clinically-validated digital therapeutic solutions into mainstream healthcare through education, advocacy, and research.

With more than a decade of experience in the healthcare industry, Megan’s expertise extends from strategic growth and partnership development within the digital health sector, to the direct delivery of patient care. Prior to joining DTA, Megan worked with Voluntis, Iodine, the Pharmaceutical Care Management Association, and the Pharmacy Technician Certification Board.

A proud Badger, Megan graduated from the University of Wisconsin—Madison School of Pharmacy and completed an Executive Residency in Association Management & Leadership with the American Pharmacists Association.

Abhishek Shah

CEO, Wellthy Therapeutics

Abhishek is the Co-founder and CEO of Wellthy Therapeutics, a digital therapeutics company which inspires and enables people to prevent and manage their chronic health conditions and is in the process, pioneering an entirely new category of medicine in Asia.

Wellthy’s first therapeutic in Type-II diabetes has been endorsed as a prescription-grade intervention by the RSSDI, Asia’s largest Diabetes research organisation and is currently prescribed by over 300 physicians in India. Since its inception in 2015, Wellthy has conducted over 13 research studies to validate it outcomes, enrolled more than 7000 participants, collected over a million behavioral data points and entered into strategic partnerships with over 7 enterprises across healthcare to transform the preventive care landscape in emerging markets.

Abhishek holds a B.S. in Chemical and Biomolecular Engineering from The Georgia Institute of Technology and an MBA from the Indian School of Business (ISB).

Abhishek has previously spoken about the role of digital therapeutics in addressing the chronic disease burden at several conferences including 78th Scientific Session of the American Diabetes Association in Orlando, The Clinically Validated Digital Therapeutics Summit in Boston, the NASSCOM Healthtech Summit in Bangalore and the Health and Retirement Conference organised by the Singapore Actuarial Society.

Chin-Wei Soo

Global Regulatory Head, Combination Products and Devices, Genentech

Chin-Wei Soo is the Global Regulatory Head, Combination Products and Devices at Roche/Genentech. He is accountable to provide technical regulatory oversight to Roche’s entire device, combination product, and digital health portfolio, covering all large (BLA) and small molecules (NDA) throughout the product lifecycle. Chin has built a global regulatory team and led the team to secure regulatory approvals for combination products globally.

Chin has 18 years of regulatory and quality experience, including strong expertise in combination products and digital health. Prior to joining Genentech, he was with Medtronic and Boston Scientific where he successfully led regulatory submissions and implemented quality management principles that resulted in approvals of IN.PACTTM drug-device coated balloon, TAXUSTM drug-device coated stent, and implantable, programmable drug infusion pumps.

Chin graduated from Iowa State University with a Bachelor degree in Industrial and Manufacturing Systems Engineering, a Master of Science in Bioscience regulatory affairs from the Johns Hopkins University, and a Doctorate in Regulatory Policy from the University of Southern California School of Pharmacy.

Derek Cothran

Senior Vice President, Client Strategy and Development, EnvoyHealth

As Senior Vice President of client strategy and development, Derek designs and implements strategies for EnvoyHealth clients. His team ensures that clients can access existing and emerging solutions. Derek has more than 15 years of healthcare experience. He has held various roles at Lash Group, an AmerisourceBergen company, including vice president of operations. He also led Lash Group’s strategic account management team, which provided strategic insight and planning to support biotech and pharmaceutical manufacturers.

Derek received a master’s degree in health administration and business and a Bachelor of Science from the University of South Carolina. Since 2014, he has served on the board of directors for a free medical clinic for low-income residents of Charlotte, North Carolina.

Iana Dimkova

Director, Healthcare Investing, GE Ventures

Iana Dimkova is a Director on the GE Ventures Healthcare Investing team where she invests in healthcare tech, tech-enabled services and life sciences startups.

Prior to joining the GE Ventures team, Iana was with ProCure Treatment Centers. At ProCure she helped develop and operate the most extensive network of radiation (proton) therapy centers in the United States. During her tenure there, the company raised more than $700M and secured strategic investments from large healthcare systems and independent physician groups. After leaving ProCure, she joined Alvarez & Marsal’s Healthcare Group, where she focused her time on helping private equity firms evaluate potential investments and improve operations at their healthcare services and MedTech portfolio companies.

Iana earned her MBA from Columbia University and received her bachelor’s degree, with honors, also from Columbia University.

Jeff Gombala

Associate Principal, ZS Associates

Jeff Gombala is an Associate Principal in ZS’ Philadelphia, PA office, focused on leading the solution design and development space in ZS' Digital and Connected Health practice. Jeff has over 18+ years of broad experience advocating agile and lean UX methodologies to develop high impact technology solutions spanning diverse domains such as healthcare, financial, military/defense, and mortgage industries.

Maurice Solomon

Associate Principal, ZS Associates

Maurice Solomon is an Associate Principal in ZS’ Los Angeles office, focused on Digital and Connected Health. He has over a decade of experience in digital health, spanning the full solution innovation lifecycle from business case and concept development through pilot and multi-country commercial scale.

Brad Burkett

Founder & Managing Partner, Match Point Partners LLC

Mr. Burkett is the Managing Partner at Match Point Partners, a firm which assists emerging Digital Health companies in investment banking and strategy. He has significant operating experience in emerging to mid-stage Digital health and healthcare services firms. He has served as Chief Executive Officer of 8 venture-backed companies, including BigWhiteWall, Acupera, Inc., CareGuide, Inc. and Oncure Medical Inc. He has also served as a Board member to Prodigy Health Group and several other firms and been a senior executive and an investor in many others. This blend of advisory experience, coupled with entrepreneurial, operational and leadership positions in healthcare and technology gives Mr. Burkett a unique perspective and allows him to deliver value-added advice to his clients tempered by operational and entrepreneurial experience.

Kal Patel, MD

President, BrightInsight, a Flex Company

Kal Patel has over 20 years of experience in pharma, medtech and regulated digital health. Prior to joining BrightInsight, he was Chief Commercial Officer for Doctor on Demand, now the nation’s largest video-medicine provider, with backing from Andreessen Horowitz, Venrock, Google Ventures, and Qualcomm.

Kal founded and built Amgen’s Digital Health business unit where he had end-to-end responsibility for developing and commercializing a portfolio of digital products in connected devices, advanced algorithms/decision making and next-generation marketing, where he launched multiple regulated devices. Kal also serves as a Senior Advisor in Digital Health to the Boston Consulting Group and various digital health startups.

Antoun Nabhan

Vice President, Corporate Development, Pear Therapeutics

Kiran Hegde

Head, BD&L, Search and Evaluation, Sandoz

David Keene

Chief Technology Officer, Dthera Sciences

David Keene was appointed as Dthera’s Chief Technology Officer and a member of Dthera’s Board of Directors in connection with the EveryStory Transaction. Mr. Keene, the founder of EveryStory and a member of EveryStory’s Board of Directors, is a veteran of the video game industry who has specialized in commerce and content delivery. Prior to founding EveryStory, from 2010 to 2013, Mr. Keene served as Chief Architect – Commerce Platform for Trion Worlds, Inc. At Trion, Mr. Keene led a group of senior engineers to create an innovative, world class commerce platform. Prior to Trion, Mr. Keene served as Senior Architect for the Sony PlayStation Network. While at Sony, Mr. Keene managed integrations with multiple global partner groups, added search and recommendation systems and oversaw the development of Sony’s content delivery and online commerce worldwide. He has advised and contributed to the commerce systems for many popular video game franchises.

Pierre Leurent

Chief Executive Officer, Voluntis

Pierre Leurent, CEO and founder of VOLUNTIS, has more than 19 years of international experience in digital health in the United States and Europe. Voluntis’ mission is to improve the real-world value of therapies by providing patients and clinicians with therapeutic companion software. Its clinical-grade, regulatory-cleared mobile and cloud solutions embed advanced real-time decision support algorithms to enable patients to better manage their treatment in remote collaboration with their healthcare team. Prior to starting Voluntis in 2001, Pierre worked at GE Medical Systems, where he took part in the development of medical imaging software. He also occupied several positions at HealthCenter Internet Services, a San Francisco-based vendor of electronic medical record solutions.

Martin Culjat

Vice President, Scientific & Regulatory Affairs, Dthera Sciences

Bryce Williams

Vice President, Lifestyle Medicine, Blue Shield of California

Michael Fahmy

Senior Director, Global Regulatory Affairs, Otsuka

“I really enjoy DTx. The focused agenda keeps the audience well engaged and I learn a lot from the diverse insights and perspectives from the audience. It’s fantastic to have such a cross-sector showing at the summit”

Joris Van Dam, Executive Director, Head of Digital Therapeutics, Novartis

Conference Workshops

Tuesday, February 26th 2019

Conference Workshops at DTx West have been specifically designed to enhance attendee’s learning experiences at the event.

These three-hour sessions will allow you to have your fundamental questions answered by experts in great detail.

If you are looking to understand the basics of Digital Therapeutics and/or you are from a Pharma seeking to learn more about digital therapeutics from a Pharma perspective, then look no further.

Click to download full details of the conference workshops.

Workshop Leaders

Jeffrey Abraham, Vice President, Market Access & Trade, Akili Interactive
Stacey Curtiss, Senior Director & Leader, Medical Science Liaisons, Akili Interactive
9:00  Presentation: What is the Current State of Play with the Digital Therapeutics Industry?
9:30  Breakout Discussions

Splitting into smaller working groups, each group will discuss their current views on digital therapeutics as a concept and their views on the different facets of the industry.

  • Are we comfortable with the definition of a digital therapeutic?
  • Generally speaking, how do payers, pharma and regulatory authorities view digital therapeutics?
  • What lessons can we draw on from working with other related industries?
  • What are our thoughts on the other similar digital medicine approaches out there?
  • What remaining questions do we have about digital therapeutics?
10:30  Refreshment Break
11:00  Feedback Discussions

Representative(s) from each group share the main points from their discussion to the whole group. Additional questions form moderators and other group members will be raised during this collaborative discussion.

12:00  End of Workshop

Leave this workshop with: 

  • Fundamental questions answered around what a digital therapeutic is being defined as compared to other digital interventions
  • A deeper understanding of the current payer and provider perspectives on digital therapeutics and how these are looking to be advanced
  • Up-to-date information on the different ways pharma are involved in the industry
  • A fundamental understanding of the current regulatory pathways in and around the industry
  • A stronger appreciation of the crucial questions facing the industry that will be tackled during the rest of the Summit

Workshop Leaders

James Musick, Vice President & Head, Neurology Patient Technology, UCB
Sasha SaidVice President, Leerink Transformation Partners
Florian SchubertDirector, Digital Strategy, Sandoz
Chris Wasden, Head of Pharma, Happify
1:00  Presentation: What are the Current Sentiments from Pharma Towards Digital Therapeutics?
1:30  Breakout Discussions

Splitting into smaller working groups, each group will discuss their own thoughts and pharma’s current
thoughts on digital therapeutics and what it is going to take to make DTx-pharma partnerships successful.

  • What is our understanding of the expectations from different types of DTx-pharma partnerships?
  • How do digital therapeutics fit into the short-term and long-term goals of pharma?
  • Are pharma more excited about the therapeutic entity or the data produced by digital therapeutics?
  • How should pharma adapt their mindsets to maximize the impact of their work with digital therapeutics?
  • How do digital therapeutic companies needs to adapt to maximize the impact of their work with pharma?
2:30  Refreshments
3:00  Feedback Discussions

Representative(s) from each group share the main points from their discussion to the whole group. Additional questions form moderators and other group members will be raised during this collaborative discussion.

4:00  End of Workshop

Leave this workshop with: 

  • Deeper understanding of the current ways pharma are partnering with digital therapeutics companies
  • Full clarification on the expectations pharma have when in a working partnership with digital therapeutic companies compared to purely investing in them
  • Discussion points around how pharma currently view digital therapeutics in their short-term and long-term strategies
  • Understanding around how different departments in pharma will impact their work in this industry and where a change of mindset is needed
  • An understanding of why some pharma are still reluctant to partner with digital therapeutic companies

Summit Agenda

Click to download our full event agenda.

8:00  Registration, Breakfast & Networking
9:00  Chair’s Opening Remarks & Setting the Scene

Joel Sangerman, Chief Commercial Officer, Click Therapeutics

Digital Therapeutics: Setting-up for Commercial Success
9:10  Presentation: The Economic Value Proposition of Digital Therapeutics

Anand Iyer, Chief Strategy Officer, WellDoc

9:30  Presentation: From Theory to Impact: Lessons Learned from Scaling Digital Medicine in the UK & US

Peter Hames, Co-Founder & Chief Executive Officer, Big Health

9:50  Panel: What is it Going take for Digital Therapeutics to Succeed Commercially?

Anand Iyer, Chief Strategy Officer, WellDoc
Eddie Martucci, Chief Executive Officer, Akili Interactive
Brent Vaughan, Chief Executive Officer, Cognoa
Alex Waldron, Chief Commercial Officer, Pear Therapeutics
David Lee, Partner, Simon Kucher & Partners

10:30  Morning Refreshments & Networking
11:00                                                                Under the Microscope: Crucial DTx Questions

These small group discussions provide a unique opportunity to get into the key detail of the challenges and opportunities of crucial questions facing digital therapeutics. Each session has been curated to bring expert moderators together in order for attendees to find questions in a peer-to-peer format.  

Attendees will be able to attend 3 roundtables, which are 30 minutes each. Get ready for plenty of takeaways in this 90 minute session!

Roundtable 1: Transitioning and Evolving Towards Digital Therapeutics

Ed Cox, Chief Executive Officer, Dthera Sciences
Martin Culjat, Vice President, Scientific & Regulatory Affairs, Dthera Sciences
David Keene, Chief Technology Officer, Dthera Sciences

Roundtable 2: Building Go-to-Market and Partnership Strategies for US and European Markets

Giangiacomo Rocco di Torrepadula, Chief Executive Officer & Co-Founder, AMICOMED
Vishal Dubey, Chief Product Officer, AMICOMED

Roundtable 3:  Putting the Patient at the Center:  Convergence of Patient Services and Digital Therapeutics

Jeff Gombala, Associate Principal, ZS Associates
Maurice Solomon, Associate Principal, ZS Associates

Roundtable 4: Working with a Payer – From Medical Policy to Commercialization

Debra Reisenthel, Founding CEO, Palo Alto Health Sciences
Matthew Tucker, Executive Director, Marketing Strategy, Highmark Health

Roundtable 5: Digital Therapeutics and Pharma Partnership Models

Antoun Nabhan, Vice President, Corporate Development, Pear Therapeutics
Kiran Hegde, Head, BD&L, Search and Evaluation, Sandoz
Joe Slavinsky, VP, Business Development, Propeller Health

Roundtable 6:  What do Digital Therapeutic Companies need to Display to Investors to Secure Funding?

Sasha Said, Vice President, Leerink Transformation Partners

12:30  Lunch & Networking
Building for Long-Term Success and Scalability
1:45  Presentation: The Evolution of Digital Therapeutics Commercialization and Scalability

Matt Cook, Vice President, Commercial Strategy & Business Development, Omada Health

2:10  Presentation: Breaking Down Silos: Why Digital Health Solutions Need the Ecosystem to Succeed

Kal Patel, MD, President, BrightInsight, a Flex Company

2:35  Presentation: Digital Therapeutics Commercialization:  Market Access Support Drives Digital Therapeutic Success

Derek Cothran, Senior Vice President, Client Strategy and Development, EnvoyHealth

3:00  Panel: Why are Companies Now Starting to Pivot Toward Digital Therapeutics?

Moderator: Adam Kaufman, President & Chief Executive Officer, Canary Health
Megan Jones-Bell, Chief Scientific OfficerHeadspace
Ed Cox, Chief Executive OfficerDthera Sciences
David Stevenson, Managing Director, Merck Global Health Innovation Fund

3:40   Afternoon Refreshments & Networking
4:15  Presentation: Scalable Digital Tools for Detecting and Training Clinical Inattention Early in Life

Kim Cornish, Director, Monash Institute of Cognitive & Clinical Neurosciences (MICCN), Monash University | Co-Inventor of Tali Train, Tali Health

Adoption and Implementation
4:30  Panel: The In’s and Out’s of the Regulatory Approval Pathways

Moderator: David Amor, Vice President, Quality & Regulatory AffairsPear Therapeutics
Taylor Mahan-Rudolph, Director, Quality & RegulatoryPropeller Health 
Austin Speier, Chief Strategy Officer, Click Therapeutics
Chin-Wei Soo, Global Regulatory Head, Combination Products and Devices, Genentech, a Member of the Roche Group
Michael Fahmy, Senior Director, Global Regulatory Affairs, Otsuka

5:10  Panel: How do Digital Therapeutics need to Adapt to The Healthcare System to be Routinely Prescribed?

Moderator: Sharief Taraman, Chief Medical OfficerCognoa | Chief of Neurology,  Children’s Hospital of Orange County
Rosemary Ku
, Urgent Care PhysicianKaiser Permanente  |  Founder, Executive Director, Cure Chronic Disease
Stephanie Tilenius, Chief Executive Officer & Founder, Vida Health
Veera Anantha, Founder, CTO & President, The Learning Corp

5:50  Drinks Reception
Download Agenda to access full details of the event…
8:00  Breakfast & Networking
9:00  Chair’s Opening Remarks

Mette Dyhrberg, Chief Executive Officer, Mymee

9:05  Presentation: Digital Therapeutics: Pursuing the Next Phase of Industry Evolution

Megan Coder, Executive Director, Digital Therapeutics Alliance

9:20   Presentation: Financing and Growing Digital Therapeutic Companies

Brad Burkett, Founder & Managing Partner, Match Point Partners LLC

Pharma & Digital Therapeutics
9:40   Presentation: Commercializing and Scaling Prescription Digital Therapeutics

André Heeg, Head of Digital, Sandoz

10:05  Panel: Pharma and Digital Therapeutics: A Match Made in Heaven?

Moderator: Pierre Leurent, Chief Executive Officer, Voluntis
André Heeg
, Head of Digital, Sandoz
Ruchita Sinha, Senior Director, Investment, Sanofi Ventures
Javier Garcia Palacios, Director, Digital Health Ventures, Bayer, #G4A

10:45  Morning Refreshments & Networking
The Next Wave of Digital Innovation
11:15  Presentation: European Perspective on Digital Therapeutics – Fitting into Universal Healthcare Systems and Beyond

Matthias Zenker, Partner, GAIA AG

11:35  Presentation: Evidence-based Digital Interventions Using Music and Neuroscience

Brian Harris, Co-Founder & CEO, MedRhythms Inc.

11:55  Presentation: Pivoting from Digital Health to Digital Therapeutics in Alcohol Behavioural Change

Chris Raine, Founder & Chief Executive Officer, Hello Sunday Morning

12:15  Presentation: How to Build and Scale Digital Therapeutics in Emerging Markets?

Abhishek Shah, Chief Executive Officer, Wellthy Therapeutics

12:35   Presentation – Digital Therapeutics Payor Adoption

Bryce Williams, Vice President, Lifestyle Medicine, Blue Shield of California

12:55   Lunch & Networking
Digital Therapeutic Market Consolidation
1:55  Panel: How and When Will the Digital Therapeutics Market Consolidate?

David Kim, CEO, DigiTx Partners
Owen McCarthy, Co-Founder & President, MedRhythms Inc.
Shahram Seyedin-Noor, Founder & General Partner, Civilization Ventures
Iana Dimkova, Director, Healthcare Investing, GE Ventures

2:35  Chair’s Summary

Mette Dyhrberg, Chief Executive Officer, Mymee

2:40  Close of DTx West 2019
Download Agenda to access full details of the event…

“DTx is a great event! There is a great mix of digital innovators and large companies which deliver high-quality content. I learn a lot and it’s great to see this community come together and have authentic interactions”

Adam Kaufman, CEO, Canary Health

DTx West Venue

The Marriott, San Mateo

We strive to provide inspirational venues that can provide the space needed for an open and widely networked event.

The 2020 summit is back at the Marriott San Mateo,  a contemporary hotel just 10 minutes from SFO airport.  For 2020 space is bigger and better.

Blending the look and feel of a first class resort with comfort and state of the art conference amenities this venue is the perfect place for learning, networking and relaxing.

Bedrooms can be booked directly with the hotel.  We anticipate high demand and recommend that you book early to secure the best possible rate.  The Marriott does not offer an exclusive rate for DTx attendees.  We have included, in the welcome pack, details of alternative hotels close to the DTx venue.



The DTx summits are the premier events for senior executives from DTx companies, Pharma, Investors, HCPs and Payers.

DTx West 2019 is the third summit in the series, the first two were sell-outs.  We are expecting 200 people at the summit in San Mateo, which is what our attendees and sponsors tell us is the optimum size

We believe that getting the right mix of sponsors is critical for a successful summit for you and our attendees.  The DTx summit provides a rare opportunity to showcase your business to a world class audience.

You will be impressed with our service and truthfulness.  We will be honest with you throughout the process from deciding which option is right for you to delivery on-site.

With 5 companies confirmed pre-launch, sponsor and supporter spaces are selling fast. Get in touch today to learn more to avoid missing out!

Contact Us

Register For The Event

Registration and pre-launch prices opens in September 2019

For pricing and booking options please click the button to go to the registration page.